Revolution Medicines achieved a $30B valuation as a pre-commercial company because investors see it as a franchise with a deep portfolio of RAS inhibitors and next-gen combinations. This platform approach, promising a durable series of improved therapies, commands a much higher multiple than a single-asset company.

BridgeBio's founder saw biotech VCs exclusively funding high-risk "home run" platforms. He built a company to acquire therapies for smaller rare genetic diseases—"singles and doubles"—that were ignored. Aggregating these de-risks the portfolio and creates a major market opportunity.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

Successful acquisitions don't just benefit the acquired company's investors. These investors often reinvest their profits into new, earlier-stage ventures, providing crucial capital that fuels the entire biotech ecosystem's growth and innovation.

The merger between Warp Drive and Revolution Medicines succeeded because a single VC firm, Third Rock, was a major investor in both. This created a neutral party to catalyze the deal, overcoming the typical ego, valuation, and investor alignment issues that kill most private-to-private mergers.

FCDI launched multiple clinical-stage companies (Century, Opsis, Kenai) by providing a proven iPSC technology backbone. This "platform and spinout" model allows new ventures to focus on clinical development rather than early platform discovery, increasing their chances of success and attracting partners.

Venture capital is shifting towards creating new companies from multiple de-risked assets acquired from large pharma. Bain's $300M investment to build a company around five BMS assets, led by a proven CEO, exemplifies this strategy. It mirrors previous successes like SpringWorks and minimizes single-asset failure risk.